The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
2025
Tumor Upstaging in Invasive Melanoma Linked to Worse Survival Outcomes
Shortfalls in clinical management may explain why tumor upstaging in invasive melanoma is associated with worse survival outcomes, according to study findings published in the Journal of the American Academy of Dermatology.
mmune Checkpoint Inhibitors for Advanced Melanoma: 10-Year Outcomes Turn Heads
The final, 10-year results of the international randomised clinical trial known as CheckMate 067 report that the median overall survival with advanced melanoma is nearly 72 months with the combination of nivolumab + ipilimumab, nearly 37 months with nivolumab monotherapy, and only 20 months with ipilimumab monotherapy. Both agents are immune checkpoint inhibitors, but their immune targets differ.
Melanoma survival linked to tumor thickness
Researchers at The University of Sydney have identified a significant increase in melanoma-related death risk for patients with thin primary tumors measuring between 0.8 and 1.0 millimeters compared to those with thinner lesions.